Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Di Pastena F, Pond G, Tsakiridis EE, Gouveia A, Ahmadi E, Biziotis OD, Ali A, Swaminath A, Okawara G, Ellis PM, Abdulkarim B, Ahmed N, Robinson A, Roa W, Valdes M, Kavsak P, Wierzbicki M, Wright J, Steinberg G, Tsakiridis T. Di Pastena F, et al. Among authors: tsakiridis t. Radiat Oncol. 2024 Nov 7;19(1):155. doi: 10.1186/s13014-024-02546-y. Radiat Oncol. 2024. PMID: 39511611 Free PMC article. Clinical Trial.
A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574).
Nguyen NA, Isfahanian N, Pond G, Hanna W, Cutz JC, Wright J, Swaminath A, Shargall Y, Chow T, Wierzbicki M, Okawara G, Quan K, Finley C, Juergens R, Tsakiridis T. Nguyen NA, et al. Among authors: tsakiridis t. Clin Lung Cancer. 2017 Jul;18(4):436-440.e1. doi: 10.1016/j.cllc.2017.01.007. Epub 2017 Jan 31. Clin Lung Cancer. 2017. PMID: 28215851 Clinical Trial.
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α.
Biziotis OD, Tsakiridis EE, Ali A, Ahmadi E, Wu J, Wang S, Mekhaeil B, Singh K, Menjolian G, Farrell T, Abdulkarim B, Sur RK, Mesci A, Ellis P, Berg T, Bramson JL, Muti P, Steinberg GR, Tsakiridis T. Biziotis OD, et al. Among authors: tsakiridis t, tsakiridis ee. Mol Oncol. 2023 Nov;17(11):2235-2256. doi: 10.1002/1878-0261.13508. Epub 2023 Aug 27. Mol Oncol. 2023. PMID: 37584455 Free PMC article.
Metformin for chemo-radio-sensitization of NSCLC.
Tsakiridis T, Skinner H, Pond G, Swaminath A, Wright J. Tsakiridis T, et al. Radiother Oncol. 2016 Aug;120(2):363-4. doi: 10.1016/j.radonc.2016.06.018. Epub 2016 Jul 9. Radiother Oncol. 2016. PMID: 27401403 No abstract available.
Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
Swaminath A, Wierzbicki M, Parpia S, Wright JR, Tsakiridis TK, Okawara GS, Kundapur V, Bujold A, Ahmed N, Hirmiz K, Kurien E, Filion E, Gabos Z, Faria S, Louie AV, Owen T, Wai E, Ramchandar K, Chan EK, Julian J, Cline K, Whelan TJ. Swaminath A, et al. Among authors: tsakiridis tk. Clin Lung Cancer. 2017 Mar;18(2):250-254. doi: 10.1016/j.cllc.2016.08.002. Epub 2016 Oct 3. Clin Lung Cancer. 2017. PMID: 27876603 Clinical Trial.
72 results